Companies › Shanghai Pharmaceuticals Holding
6 active drug programs in 10 registered trials: 5 Phase 2, 5 Phase 1; Oncology, Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SPH4336 | – | Phase 2 | Locally Advanced or Metastatic Breast Cancer; Breast Cancer Brain Metastases; Advanced Solid Tumors | Dec 2026 |
| LT3001 | – | Phase 2 | Acute Ischemic Stroke | Dec 2026 |
| SPH5030 HER2 tyrosine kinase inhibitor | – | Phase 2 | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | Dec 2026 |
| SPH9788 | – | Phase 1 | Healthy Participants | Dec 2026 |
| T3011 Intratumoral immunotherapy agent | – | Phase 1 | Advanced Melanoma; Advanced Solid Tumors | Dec 2026 |
| SPH7485 | – | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05744687 | SPH4336 | Phase 2 | Locally Advanced or Metastatic Breast Cancer | Oncology | May 2026 |
| NCT06214156 | T3011 | Phase 1 | Advanced Melanoma | Oncology | Sep 2026 |
| NCT05860465 | SPH4336 | Phase 2 | Locally Advanced or Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT05686642 | LT3001 | Phase 2 | Acute Ischemic Stroke | Neurology | Dec 2026 |
| NCT06434597 | SPH5030 | Phase 2 | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | Oncology | Dec 2026 |
| NCT05872347 | SPH4336 | Phase 2 | Breast Cancer Brain Metastases | Oncology | Dec 2026 |
| NCT05944224 | SPH4336 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT06214143 | T3011 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT06839131 | SPH9788 | Phase 1 | Healthy Participants | Other | Dec 2026 |
| NCT06487455 | SPH7485 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
No annotated target.
–
Abbisko Therapeutics Multitude Therapeutics Avistone Biotechnology DualityBio TORL Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.